Unmet Need in Lupus Nephritis Finally Addressed with New FDA Approvals for GlaxoSmithKline’s BENLYSTA (belimumab) and Aurinia Pharmaceuticals’ LUPKYNIS (voclosporin)
According to Spherix Global Insights, rheumatologists and nephrologists are excited about new treatment options in addition to a multitude of pipeline compounds for patients with lupus nephritis EXTON, Pa., January 25, 2021 /PRNewswire/ —According to a survey of more than 200 US rheumatologists and nephrologists in mid-2020, the unmet need for new treatments for lupus nephritis […]
Nephrologists Attending the American Society of Nephrology Virtual Meeting Point to New Data on the SGLT2 Inhibitor Class as Being the Most Compelling Presented at the Conference
According to Spherix Global Insights, nephrologists overwhelmingly chose the DAPA-CKD trial as the most compelling among the eight presented during the oral abstract session, “High Impact Clinical Trials” EXTON, Pa., / November 2, 2020 / PRNewswire – With virtual conferences being the standard for the foreseeable future, Spherix Global Insights sought to gather feedback from […]
Rheumatologists and Nephrologists Anxiously Await New Potential Treatments for Systemic Lupus Erythematosus and Lupus Nephritis, According to Spherix Global Insights
Lupus has high unmet needs and a very active pipeline, including AstraZeneca’s anifrolumab, Eli Lilly’s Olumiant, novel TYK-2 inhibitors from Pfizer and Bristol Myers Squibb, as well as a potential label expansion for GlaxoSmithKline’s Benlysta for renal manifestations EXTON, Pa., September 30, 2020 /PRNewswire/ — Rheumatologists have long struggled to effectively treat patients with systemic […]
Despite Most Specialty Physician Practices Reopening, Engagement with the Pharmaceutical Industry Continues to be Largely Virtual, Placing Added Pressure on Manufacturers Attempting to Introduce New Therapies
Though surveyed US specialists report shrinking trepidation prescribing certain drugs amid the COVID-19 pandemic, hesitation to prescribe new brands remains EXTON, Pa., September 15, 2020 / PRNewswire / – In March, Spherix began tracking the impact of COVID-19 among specialty physicians, specifically dermatologists, gastroenterologists, nephrologists, neurologists, and rheumatologists. In each wave, approximately 250 specialists share […]
SGLT2 Inhibitors Could Induce a Seismic Shift in Treatment of Diabetic Kidney Disease in the US, According to Spherix Global Insights
The SGLT2 inhibitor class, specifically Janssen’s Invokana (promoted by Relypsa in nephrology), is gaining momentum with nephrologists as potential DKD indications loom for AstraZeneca’s Farxiga and Boehringer Ingelheim/Eli Lilly’s Jardiance EXTON, Pa., / September 8, 2020 / PRNewswire – With the increasing prevalence of diabetes across the United States, concern about diabetic kidney disease (DKD) […]
Nephrologists Point to Profound Unmet Need for New Agents to Treat Glomerular Diseases Such as IgA Nephropathy, Focal Segmental Glomerulosclerosis (FSGS), and Lupus Nephritis
According to Spherix Global Insights, nephrologists anxiously await pipeline products such as Retrophin’s sparsentan, Aurinia’s voclosporin, Reata’s bardoxolone methyl, and Calliditas’ NEFECON to offer new options for patients suffering with these conditions EXTON, Pa., / August 31, 2020 / PRNewswire – Glomerular diseases pose some of the greatest challenges to nephrologists: they are progressive and […]
Spherix Global Insights Releases 2021 Publication Plan and Announces New Service, Launch Dynamix™, Fueled by Growing Client Demand
The firm, which was recently recognized by Philadelphia Business Journal as one of the area’s Soaring 76 fastest growing companies for the second year in a row, continues to invest in its areas of deep expertise: dermatology, gastroenterology, nephrology, neurology, and rheumatology EXTON, Pa., August 27, 2020 /PRNewswire/ — Since its founding in 2015, Spherix […]
The US Hyperkalemia Market Remains a Battle Ground Between AstraZeneca’s LOKELMA (zirconium sodium cyclosilicate) and Vifor/Relypsa’s VELTASSA (patiromer FOS)
According to a recently published report by Spherix Global Insights, after rapid trial of Lokelma in hyperkalemia, treatment patterns are beginning to settle in – with each competitor starting to dominate in certain patient types EXTON, Pa., / August 24, 2020 / PRNewswire – Despite the recent emergence of new therapeutic options to treat hyperkalemia, […]
Primary Care Providers Report High Prevalence of Chronic Kidney Disease and Categorize It as One of the Most Challenging Conditions to Manage
An independent audit conducted by Spherix Global Insights analyzed the charts of more than 1,000 patients with moderate to severe kidney disease who had not yet been referred to a nephrologist EXTON, Pa., August 13, 2020 /PRNewswire/ — According to the National Kidney Foundation, one in three Americans over the age of 20 (a striking […]
Treatment of Anemia Among Hematology/Oncology Specialists Spans Diverse Patient Types, Many of Which Have Multiple Contributory Factors
According to Spherix Global Insights, the potential approval of the hypoxia-inducible factors prolyl-hydroxylase inhibitors could alter referral and treatment patterns for patients with anemia of chronic kidney disease being managed by hematologists/oncologists. EXTON, Pa., July 14, 2020 / PRNewswire / – Spherix recently fielded a survey of 152 hematologists/oncologists in the US in order to […]
